Your browser doesn't support javascript.
loading
A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus.
Farmakis, Dimitrios; Agostoni, Piergiuseppe; Baholli, Loant; Bautin, Andrei; Comin-Colet, Josep; Crespo-Leiro, Maria G; Fedele, Francesco; García-Pinilla, Jose Manuel; Giannakoulas, George; Grigioni, Francesco; Gruchala, Marcin; Gustafsson, Finn; Harjola, Veli-Pekka; Hasin, Tal; Herpain, Antoine; Iliodromitis, Efstathios K; Karason, Kristjan; Kivikko, Matti; Liaudet, Lucas; Ljubas-Macek, Jana; Marini, Marco; Masip, Josep; Mebazaa, Alexandre; Nikolaou, Maria; Ostadal, Petr; Põder, Pentti; Pollesello, Piero; Polyzogopoulou, Eftihia; Pölzl, Gerhard; Tschope, Carsten; Varpula, Marjut; von Lewinski, Dirk; Vrtovec, Bojan; Yilmaz, Mehmet Birhan; Zima, Endre; Parissis, John.
Afiliação
  • Farmakis D; University of Cyprus Medical School, Nicosia, Cyprus; Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: farmakis.dimitrios@ucy.ac.cy.
  • Agostoni P; Centro Cardiologico Monzino, IRCCS, Milan, Italy; Dept. of Clinical Sciences and Community Health - Cardiovascular Section, University of Milan, Milan, Italy.
  • Baholli L; Medizinische Klinik Mitte - Schwerpunkte Kardiologie und Internistische Intensivmedizin, Klinikum Dortmund gGmbH, Dortmund, Germany.
  • Bautin A; Department of Anesthesiology, Almazov National Medical Research Center, Saint Petersburg, Russia.
  • Comin-Colet J; Heart Diseases Institute, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Spain.
  • Crespo-Leiro MG; Complexo Hospitalario Universitario de A Coruña (CHUAC)-CIBERCV, Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain.
  • Fedele F; Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, 'La Sapienza' University of Rome, Rome, Italy.
  • García-Pinilla JM; Heart Failure and Familial Cardiopathies Unit, Cardiology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Giannakoulas G; Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Grigioni F; Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
  • Gruchala M; First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
  • Gustafsson F; Cardiology Dept., Rigshospitalet, University of Copenhagen, Copengahen, Denmark.
  • Harjola VP; Emergency Medicine, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
  • Hasin T; Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Herpain A; Department of Intensive Care, Experimental Laboratory of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Bruxelles, Belgium.
  • Iliodromitis EK; Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Karason K; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Kivikko M; Department of Cardiology S7, Jorvi Hospital, Espoo, Finland; Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.
  • Liaudet L; Service de Médecine Intensive Adulte et Centre des Brûlés, Centre Hospitalier Universitaire Vaudois et Faculté de Biologie et Médecine, Lausanne, Switzerland.
  • Ljubas-Macek J; Department for Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.
  • Marini M; Department of Cardiovascular Sciences, Ospedali Riuniti, Ancona, Italy.
  • Masip J; Intensive Care Dpt. Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain; Cardiology Department, Hospital Sanitas CIMA, Barcelona, Spain.
  • Mebazaa A; Department of Anaesthesiology and Critical Care Medicine, AP-HP, Saint Louis and Lariboisière University Hospitals and INSERM UMR-S 942, Paris, France.
  • Nikolaou M; Department of Cardiology, General Hospital "Sismanogleio-Amalia Fleming", Greece.
  • Ostadal P; Cardiovascular Center, Na Homolce Hospital, Prague, Czech Republic.
  • Põder P; Department of Cardiology, North Estonia Medical Center, Tallinn, Estonia.
  • Pollesello P; Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.
  • Polyzogopoulou E; Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Pölzl G; Universitätsklinik für Innere Medizin III, Medizinsche Universität, Innsbruck, Austria.
  • Tschope C; Charité, University Medicine Berlin, Campus Virchow Klinikum (CVK), Department of Cardiology, Germany; BCRT, Berlin Institute of Health for Center for Regenerative Therapies, Berlin, Germany.
  • Varpula M; Department of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • von Lewinski D; Department of Cardiology, Myokardiale Energetik und Metabolismus Research Unit, Medical University, Graz, Austria.
  • Vrtovec B; Advanced Heart Failure and Transplantation Center, Department of Cardiology, Ljubljana University Medical Center, Ljubljana, Slovenia.
  • Yilmaz MB; Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
  • Zima E; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Parissis J; Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Int J Cardiol ; 297: 83-90, 2019 12 15.
Article em En | MEDLINE | ID: mdl-31615650
ABSTRACT
Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiotônicos / Insuficiência Cardíaca Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiotônicos / Insuficiência Cardíaca Idioma: En Ano de publicação: 2019 Tipo de documento: Article